Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Chemotherapy Induced Peripheral Neuropathy Overview | 11 | 1 |
| Pipeline Products for Chemotherapy Induced Peripheral Neuropathy Comparative Analysis | 12 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Therapeutics under Development by Companies | 13 | 2 |
| Chemotherapy Induced Peripheral Neuropathy Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Pipeline Products Glance | 16 | 3 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Products under Development by Companies | 19 | 2 |
| Chemotherapy Induced Peripheral Neuropathy Products under Investigation by Universities/Institutes | 21 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Companies Involved in Therapeutics Development | 22 | 25 |
| Achelios Therapeutics, Inc. | 22 | 1 |
| Advinus Therapeutics Ltd | 23 | 1 |
| Amplyx Pharmaceuticals, Inc. | 24 | 1 |
| Can-Fite BioPharma Ltd. | 25 | 1 |
| DermaXon, LLC | 26 | 1 |
| Eisai Co., Ltd. | 27 | 1 |
| Immune Pharmaceuticals Inc. | 28 | 1 |
| INSYS Therapeutics, Inc. | 29 | 1 |
| KPI Therapeutics, Inc. | 30 | 1 |
| Krenitsky Pharmaceuticals Inc. | 31 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 32 | 1 |
| Lpath, Inc. | 33 | 1 |
| MAKScientific, LLC | 34 | 1 |
| Metys Pharmaceuticals AG | 35 | 1 |
| Midatech Pharma US Inc. | 36 | 1 |
| Nemus Bioscience, Inc. | 37 | 1 |
| Neurocentrx Pharma Ltd. | 38 | 1 |
| Panacea Pharmaceuticals, Inc. | 39 | 1 |
| PeriphaGen, Inc. | 40 | 1 |
| PharmatrophiX, Inc. | 41 | 1 |
| PledPharma AB | 42 | 1 |
| Sova Pharmaceuticals, Inc. | 43 | 1 |
| Spectrum Pharmaceuticals, Inc. | 44 | 1 |
| Virobay Inc. | 45 | 1 |
| WEX Pharmaceuticals Inc. | 46 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment | 47 | 12 |
| Assessment by Monotherapy Products | 47 | 1 |
| Assessment by Combination Products | 48 | 1 |
| Assessment by Target | 49 | 3 |
| Assessment by Mechanism of Action | 52 | 3 |
| Assessment by Route of Administration | 55 | 2 |
| Assessment by Molecule Type | 57 | 2 |
| Drug Profiles | 59 | 61 |
| (amitriptyline + ketamine hydrochloride) Drug Profile | 59 | 4 |
| AM-1710 Drug Profile | 63 | 1 |
| AXPN-02 Drug Profile | 64 | 1 |
| BR-297 Drug Profile | 65 | 1 |
| cannabidiol Drug Profile | 66 | 3 |
| dimiracetam Drug Profile | 69 | 2 |
| Drugs for Peripheral Neuropathy Drug Profile | 71 | 1 |
| DX-0332 Drug Profile | 72 | 1 |
| E-2072 Drug Profile | 73 | 1 |
| HM-01 Drug Profile | 74 | 1 |
| ketoprofen Drug Profile | 75 | 1 |
| KP-544 Drug Profile | 76 | 1 |
| KRN-5500 Drug Profile | 77 | 4 |
| LM11A-31BHS Drug Profile | 81 | 2 |
| Lpathomab Drug Profile | 83 | 3 |
| MR-309 Drug Profile | 86 | 2 |
| NB-2111 Drug Profile | 88 | 1 |
| NRX-2922 Drug Profile | 89 | 1 |
| NT-24336 Drug Profile | 90 | 1 |
| PAN-811 Drug Profile | 91 | 2 |
| PGN-503 Drug Profile | 93 | 1 |
| piclidenoson Drug Profile | 94 | 7 |
| pirenzepine hydrochloride Drug Profile | 101 | 1 |
| PP-095 Drug Profile | 102 | 4 |
| Q-201 Drug Profile | 106 | 1 |
| Small Molecule for Pain Drug Profile | 107 | 1 |
| Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy Drug Profile | 108 | 1 |
| Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy Drug Profile | 109 | 1 |
| Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy Drug Profile | 110 | 1 |
| Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy Drug Profile | 111 | 1 |
| Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy Drug Profile | 112 | 1 |
| SPI-205 Drug Profile | 113 | 1 |
| Tetrodotoxin Drug Profile | 114 | 2 |
| U-2902 Drug Profile | 116 | 2 |
| VBY-036 Drug Profile | 118 | 1 |
| XT-150 Drug Profile | 119 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Dormant Projects | 120 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Discontinued Products | 121 | 1 |
| Chemotherapy Induced Peripheral Neuropathy Product Development Milestones | 122 | 5 |
| Featured News &Press Releases | 122 | 1 |
| Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program | 122 | 1 |
| Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA | 122 | 1 |
| Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program | 123 | 1 |
| Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA | 124 | 1 |
| Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation | 124 | 1 |
| Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development | 125 | 2 |
| Appendix | 127 | 2 |
| Methodology | 127 | 1 |
| Coverage | 127 | 1 |
| Secondary Research | 127 | 1 |
| Primary Research | 127 | 1 |
| Expert Panel Validation | 127 | 1 |
| Contact Us | 127 | 1 |
| Disclaimer | 128 | 1 |